At the time of writing, Theravance Biopharma Inc [TBPH] stock is trading at $17.78, down -3.89%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TBPH shares have gain 18.93% over the last week, with a monthly amount glided 28.38%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Theravance Biopharma Inc [NASDAQ: TBPH] stock has seen the most recent analyst activity on September 12, 2025, when B. Riley Securities initiated its Buy rating and assigned the stock a price target of $28. Previously, Leerink Partners downgraded its rating to Market Perform on August 06, 2024, and dropped its price target to $10. On April 12, 2024, BTIG Research initiated with a Buy rating and assigned a price target of $21 on the stock. Evercore ISI downgraded its rating to a In-line. SVB Leerink initiated its recommendation with a Outperform and recommended $12 as its price target on May 23, 2022. JP Morgan upgraded its rating to Neutral for this stock on November 05, 2021, but kept the price target unchanged to $12. In a note dated September 15, 2021, JP Morgan downgraded an Underweight rating on this stock but restated the target price of $7.
For the past year, the stock price of Theravance Biopharma Inc fluctuated between $7.90 and $18.96. Currently, Wall Street analysts expect the stock to reach $15.33 within the next 12 months. Theravance Biopharma Inc [NASDAQ: TBPH] shares were valued at $17.78 at the most recent close of the market. An investor can expect a potential drop of -13.78% based on the average TBPH price forecast.
Analyzing the TBPH fundamentals
According to Theravance Biopharma Inc [NASDAQ:TBPH], the company’s sales were 77.20M for trailing twelve months, which represents an 83.75% jump. Gross Profit Margin for this corporation currently stands at 0.75% with Operating Profit Margin at -0.41%, Pretax Profit Margin comes in at 0.59%, and Net Profit Margin reading is 0.2%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.08 and Total Capital is -0.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.19.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.45 points at the first support level, and at 17.13 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.09, and for the 2nd resistance point, it is at 18.41.
Ratios To Look Out For
It is important to note that Theravance Biopharma Inc [NASDAQ:TBPH] has a current ratio of 6.70. Also, the Quick Ratio is 6.70, while the Cash Ratio stands at 4.67. Considering the valuation of this stock, the price to sales ratio is 11.60, the price to book ratio is 3.98 and price to earnings (TTM) ratio is 76.02.
Transactions by insiders
Recent insider trading involved ERAN BROSHY, Director, that happened on Nov 11 ’25 when 45000.0 shares were purchased. SVP, COMM & MEDICAL AFFAIRS, Farnum Rhonda completed a deal on Jul 14 ’25 to sell 10000.0 shares. Meanwhile, Officer RHONDA FARNUM bought 10000.0 shares on Jul 14 ’25.
